Cardinal Health Inc: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 4, 2023 and accepted by EDGAR at May 4, 2023, 20:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $50.49bn | us-gaap:Revenues |
| Revenue | 9 months2022-07-01 to 2023-03-31 | $151.56bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $48.70bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-07-01 to 2023-03-31 | $146.50bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $1.78bn | us-gaap:GrossProfit |
| Gross profit | 9 months2022-07-01 to 2023-03-31 | $5.06bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $1.18bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-07-01 to 2023-03-31 | $3.57bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $572.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-07-01 to 2023-03-31 | $590.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $28.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-07-01 to 2023-03-31 | $78.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $197.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-07-01 to 2023-03-31 | $189.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $345.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-07-01 to 2023-03-31 | $325.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 258,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-07-01 to 2023-03-31 | 264,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-07-01 to 2023-03-31 | $1.98bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-07-01 to 2023-03-31 | $264.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2022-07-01 to 2023-03-31 | $399.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2022-07-01 to 2023-03-31 | $1.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $3.99bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $33.50bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $43.38bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $32.50bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2023-03-31 | −$2.22bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-015775. Last ingested by Listed: Oct 24, 2026, 14:55 ET. Listed shows no prices and gives no investment advice.